Core Viewpoint - The company, Kexing Pharmaceutical, is attempting to balance innovation and commercialization as it aims to launch an "A+H" dual-platform financing strategy by submitting its IPO application to the Hong Kong Stock Exchange, with the funds primarily allocated for R&D and high-value drug pipeline development [2] Group 1: Product Portfolio and Market Position - Kexing Pharmaceutical focuses on the development, production, and commercialization of recombinant proteins, antibodies, and targeted delivery therapies, particularly in oncology and autoimmune therapy, utilizing a "self-research + licensing" dual development model [3] - The company currently has 9 commercialized products and 15 projects in the pipeline, with 2 in Phase III clinical trials and 3 in Phase II or I, covering various treatment areas including antiviral, hematology, and oncology [3] - The core product, SINOGEN (Interferon α1b injection), is projected to dominate the Chinese short-acting interferon α1b market with a 55.2% market share in 2024, maintaining the top position for six consecutive years since 2019 [5] - EPOSINO (Erythropoietin injection) is expected to achieve a 16.7% market share in 2024, ranking second in the domestic market since 2021, with sales covering over 30 countries [5] Group 2: Financial Performance and Revenue Concentration - Kexing Pharmaceutical's revenue has shown significant volatility, with 99.6% of its income reliant on six core products, indicating a highly concentrated revenue structure [7][9] - Revenue figures for 2022 to 2024 are projected at RMB 1.316 billion, RMB 1.259 billion, and RMB 1.407 billion respectively, with net profits fluctuating from a loss of RMB 92.8 million in 2022 to a profit of RMB 27 million in 2024 [7][8] - The core products are in markets with limited growth potential, with the interferon α market expected to reach RMB 3.1 billion in 2024, growing at a compound annual growth rate (CAGR) of only 4.5% from 2019 to 2024 [9] Group 3: International Expansion and Future Prospects - The company has been expanding internationally since 2000 and is now one of the Chinese biopharmaceutical firms with the broadest overseas coverage, with overseas sales projected to reach RMB 224 million in 2024, accounting for 16% of total revenue [11] - The successful fundraising from the Hong Kong IPO could provide essential support for Kexing Pharmaceutical's R&D and international expansion efforts, but the ability to overcome growth bottlenecks will depend on the progress of innovative drug development and commercialization [12]

Core Viewpoint - The article highlights the surge in demand for flu vaccines due to a significant flu season in China, particularly in southern regions, leading to temporary shortages in various cities. Despite this demand, the leading company in the sector, Hualan Vaccine, is facing substantial declines in revenue and profit, raising concerns about its ability to convert short-term demand into sustainable performance [2][10][12]. Group 1: Flu Vaccine Demand and Market Response - The current flu season has seen a notable increase in activity levels, especially in southern China, resulting in a spike in flu vaccine demand [2][3]. - Major cities like Guangzhou, Xi'an, Changzhou, and Jinan are experiencing temporary shortages of flu vaccines at community health service centers [7]. - Hualan Vaccine, with an annual production capacity of 100 million doses, has accelerated its batch approval process in response to the increased demand, leading to a stock price increase of over 30% in just over a month [2][10]. Group 2: Company Performance and Challenges - Despite the surge in demand, Hualan Vaccine reported a significant decline in both revenue and net profit for the first three quarters of the year, with revenue down 15.81% to 806 million yuan and net profit down 50.51% to 132 million yuan [12][13]. - The company is facing a price war initiated by competitors, which has led to a decrease in both gross and net profit margins. The gross margin fell by 4.06 percentage points to 76.99%, while the net margin decreased by 11.51 percentage points to 16.42% [12][13]. - Hualan Vaccine's strategy of "exchanging price for volume" has not yet yielded the expected results, as the anticipated increase in market demand has not materialized [12].

股东询价转让结果报告书暨持股5%以上股东权益变动触及5%整数倍的提示性公告 深圳科益医药控股有限公司（以下简称"科益医药"或"转让方"）及其一致行动人邓学勤保证向科兴生物 制药股份有限公司（以下简称"公司"或"科兴制药"）提供的信息真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：688136 证券简称：科兴制药 公告编号：2025-097 科兴生物制药股份有限公司 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 重要内容提示: ● 本次询价转让的价格为30.05元/股，转让的股票数量为10,062,800股。 ● 公司控股股东参与本次询价转让。 ● 本次转让不会导致公司控股股东、实际控制人发生变化。 ● 本次权益变动后，科益医药及其一致行动人邓学勤先生合计持有本公司101,389,955股股份，占公司总 股本的比例由权益变动前的55.38%减少至50.38%。累计权益变动比例触及5%的整数倍。 一、转让方情况 (一)转让方基本情况 截至2025年11月14日转让方所持公司股份的数量、比例情况如下： ■ 本次询价转让的转让 ...

科兴生物制药股份有限公司 简式权益变动报告书 截至本报告书签署之日，除本报告书披露的持股信息外，信息披露义务人没 有通过任何其他方式增加或减少其在科兴生物制药股份有限公司中拥有权益的 股份。 上市公司名称：科兴生物制药股份有限公司 股票上市地点：上海证券交易所 股票简称：科兴制药 股票代码：688136 信息披露义务人一：深圳科益医药控股有限公司 通讯地址：深圳市南山区粤海街道科兴科学园 D1 栋 42 层 信息披露义务人二：邓学勤 通讯地址：深圳市南山区粤海街道科兴科学园 D1 栋 42 层 股份变动性质：股份减少 签署日期：2025 年 11 月 20 日 信息披露义务人声明 一、信息披露义务人依据《中华人民共和国证券法》（以下简称"《证券法》"） 《上市公司收购管理办法》（以下简称"《收购办法》"）《证券期货法律适用意见 第 19 号——<上市公司收购管理办法>第十三条、第十四条的适用意见》《公开 发行证券公司信息披露内容与格式准则第 15 号—权益变动报告书》（以下简称 "准则 15 号"）及相关的法律、法规编写本报告书。 二、信息披露义务人签署本报告书已获得必要的授权和批准，其履行亦不违 反信息披露 ...

证券代码：688136 证券简称：科兴制药 公告编号：2025-097 科兴生物制药股份有限公司 股东询价转让结果报告书暨持股 5%以上股东权益变动 触及 5%整数倍的提示性公告 深圳科益医药控股有限公司（以下简称"科益医药"或"转让方"）及其一致行动 人邓学勤保证向科兴生物制药股份有限公司（以下简称"公司"或"科兴制药"）提供 的信息真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 重要内容提示: 本次询价转让的价格为30.05元/股，转让的股票数量为10,062,800股。 本次权益变动后，科益医药及其一致行动人邓学勤先生合计持有本公司 101,389,955 股股份，占公司总股本的比例由权益变动前的55.38%减少至50.38%。 累计权益变动比例触及 5%的整数倍。 一、 转让方情况 (一)转让方基本情况 | 序号 | 股东名称 | 持股数量（股） | 持股比例 | | --- | --- | --- | --- | | 1 | 深圳科益医药控股有限公司 | 109,688,630 | 54.50% | 截至 2025 年 11 ...

中国国际金融股份有限公司 关于科兴生物制药股份有限公司 股东向特定机构投资者询价转让股份的核查报告 中国国际金融股份有限公司（以下简称"中金公司""组织券商"）受科兴生物 制药股份有限公司（以下简称"科兴制药""公司""上市公司"）股东深圳科益医 药控股有限公司（以下简称"科益医药""出让方"）委托，组织实施本次科兴制药 股东向特定机构投资者询价转让（以下简称"本次询价转让"）。 （二）本次询价转让数量 本次拟询价转让股数上限为 10,062,800 股，受让方获配后，本次询价转让情况如 下： | 转让股东名称 | 转让股份数量（股） | 占总股本比例 | 占截至2025年9月30日收 盘所持股份比例 | 转让股份来源 | | --- | --- | --- | --- | --- | | 科益医药 | 10,062,800 | 5.00% | 9.17% | 首发前股份 | （三）转让方式 出让方作为上海证券交易所科创板上市公司科兴制药首发前股东，根据《询价转 让和配售指引》有关规定以向特定机构投资者询价转让方式转让股份。 （四）本次询价转让价格下限确定原则 经核查，中金公司就本次询价转让的出让方、受让方是 ...

中国经济网北京11月18日讯 科兴制药(688136.SH)昨日晚间发布股东询价转让定价情况提示性公 告。经向机构投资者询价后，初步确定的转让价格为30.05元/股。 参与本次询价转让报价及申购的机构投资者家数为24家，涵盖了基金管理公司、合格境外机构投资 者、证券公司、私募基金管理人等专业机构投资者。参与本次询价转让报价及申购的机构投资者合计有 效认购股份数量为14,877,000股，对应的有效认购倍数为1.48倍。 科兴制药于11月14日发布股东询价转让计划书。本次拟参与科兴制药首发前股东询价转让的股东为 科益医药；出让方拟转让股份的总数为10,062,800股，占公司总股本的比例为5.00%；本次询价转让为 非公开转让，不通过集中竞价交易方式或大宗交易方式进行，不属于通过二级市场减持。受让方通过询 价转让受让的股份，在受让后6个月内不得转让；本次询价转让的受让方为具备相应定价能力和风险承 受能力的机构投资者。 本次询价转让出让方科益医药为公司控股股东，持有公司股份比例超过5%。公司董事长邓学勤通 过科益医药间接持有公司股份。 按照初步确定的转让价格为30.05元/股计算，科益医药本次询价转让股份对应总市 ...

Core Insights - The article provides an overview of the latest net asset value (NAV) rankings of various funds, highlighting the top-performing and bottom-performing funds in the market [2][4]. Fund Performance Summary Top 10 Funds by NAV Growth - The top 10 funds with the highest NAV growth as of November 17, 2025, include: 1. 东方阿尔法瑞享混合发起C: NAV 1.1144, growth 6.24% 2. 东方阿尔法瑞享混合发起A: NAV 1.1144, growth 6.22% 3. 泰信发展主题混合: NAV 2.0350, growth 4.90% 4. 泰信现代服务业混合: NAV 2.2980, growth 4.64% 5. 圆信永丰高端制造C: NAV 3.0301, growth 4.59% 6. 圆信永丰高端制造A: NAV 3.0304, growth 4.59% 7. 国寿安保低碳经济混合A: NAV 1.1454, growth 4.26% 8. 国寿安保低碳经济混合C: NAV 1.1336, growth 4.26% 9. 创金合信全球医药生物股票发起(QDII)A: NAV 1.6867, growth 4.20% 10. 创金合信全球医药生物股票发起(QDII)C: NAV 1.6721, growth 4.20% [2]. Bottom 10 Funds by NAV Decline - The bottom 10 funds with the largest NAV declines as of November 17, 2025, include: 1. 同泰大健康主题混合C: NAV 0.4961, decline -3.58% 2. 同泰大健康主题混合A: NAV 0.5053, decline -3.57% 3. 国投瑞银白银期货(LOF)C: NAV 1.3605, decline -3.56% 4. 国投瑞银白银期货(LOF)A: NAV 1.3718, decline -3.56% 5. 景顺长城医疗产业股票C: NAV 1.3737, decline -3.32% 6. 景顺长城医疗产业股票A: NAV 1.3777, decline -3.32% 7. 华富健康文娱灵活配置混合C: NAV 1.1653, decline -3.24% 8. 华富健康文娱灵活配置混合A: NAV 1.1750, decline -3.24% 9. 银华成长智选混合A: NAV 1.0716, decline -3.13% 10. 银华成长智选混合C: NAV 1.0694, decline -3.13% [4]. Market Analysis - The Shanghai Composite Index showed a downward trend, while the ChiNext Index experienced fluctuations, closing slightly lower. The total trading volume reached 1.93 trillion, with a market breadth of 2,584 gainers to 2,726 losers [6]. - The leading sectors included software services with gains exceeding 2%, while the lagging sectors were pharmaceuticals, insurance, healthcare, banking, construction materials, and securities [6]. Fund Strategy Insights - The top-performing fund, 泰信发展主题混合, is focused on the new energy sector, with a significant portion of its holdings in lithium mining companies, indicating a strong performance relative to the market [7]. - Conversely, the poorly performing fund, 同泰大健康主题混合C, is concentrated in the pharmaceutical sector, which has faced significant declines in its top holdings [7].

Core Insights - The ChiNext 100 Index rose by 0.4%, while the ChiNext Composite Index fell by 0.2%, the ChiNext 50 Index decreased by 0.5%, and the ChiNext Growth Index dropped by 0.9% [1] Sector Performance - The software sector saw most stocks rise, with BoRui Data hitting the daily limit, and PingGao Co. and StarRing Technology increasing by over 11% [1] - The lithium battery sector experienced fluctuations but trended upwards, with Rongbai Technology hitting the daily limit, Zhenhua New Materials rising over 10%, JiaYuan Technology increasing by over 5%, and Xiamen Tungsten New Energy up by over 3% [1] - The innovative drug sector faced a general decline, with Kexing Pharmaceutical and Jindike dropping over 7% [1] Fund Flow - The ChiNext 50 ETF (588080) saw a net inflow of 240 million yuan in the previous trading day [1]

北京商报讯（记者 丁宁）11月17日晚间，科兴制药（688136）发布公告称，公司已于11月6日向香港联 交所递交了发行H股股票并在香港联交所主板挂牌上市的申请，并于同日在香港联交所网站刊登了本次 发行上市的申请材料。 科兴制药表示，公司已根据相关规定向中国证监会报送了本次发行上市的备案申请材料，并于近日获中 国证监会接收。 ...